A Clinical Research Study May Be an Option for You!
IgA Nephropathy (also called Berger’s Disease) is a kidney disease characterized by the accumulation of antibodies, specifically immunoglobulin A (IgA), in kidney tissue, further giving rise to inflammation. This inflammation poses a challenge of persistent kidney discomfort, and if left untreated, can lead to serious complications in the future. Despite recent advances in chronic kidney disease treatments, there is a need for a potential treatment for IgA Nephropathy. Primary IgA Nephropathy Clinical Trial.
You may be eligible to participate in the primary IgA Nephropathy Clinical Trial if you:
- Are 18 years of age or older
- Have been diagnosed with primary IgA Nephropathy
- Additional criteria may apply
Right now, Revival Research Institute is investigating a novel drug that may help in advancing clinical research in nephrology and offer potential treatment for IgA Nephropathy. Additionally, our research aims to assess the safety & and efficacy of investigational drugs.
Men and women who suffer from chronic kidney disease and fulfill the above criteria are eligible to enroll in primary IgA Nephropathy Clinical Trial happening in Texas.
*There is no cost to you or your private medical insurance to participate in this clinical research trial. You will be monetarily compensated for your time and travel. And all participants receive study-related care from doctors & healthcare professionals, free of cost.
*If you think you might like to participate in the Berger’s Disease Study or would like more information, please enter your information so we can see if you qualify and can contact you about the study. Remember that your participation is entirely voluntary. If you do decide to take part in a study, you may change your mind about participating at any time.